Itonis Inc (ITNS)

[millionlafs]

Thoughts of an investor...

Charles Hensley, PhD., plans on doing it again! After his success of Zicam(r), one of the leaders in Cold Remedy medications, he is now looking at another success with Emesy(r).

Emesyl(R) is an anti-nausea medication, taken nasally. The main advantage to the nasal medicating route is that once nausea sets in, it is difficult to administer oral medications and keep them ingested. Another route would be anally, but as you may suspect, this is difficult in public situations.

Dr. Hensley appears well on his way to distribution of the new Emesyl(r) product. To date, Itonis Inc (ticker: ITNS), headed by Dr. Charles Hensley, has met or passed the following milestones:

Research and Developement of EMESYL(r).
Performed successful Case Studies.
Is registered for Trademark Protection.
Fully designed Packaging.
FDA approval and National Drug Code (NDC) numbered.
Now in production to create and fill 16,000 units.
Although not announced, I am sure that Dr Hensley and his team are planning sales and distribution strategies at this time.
I believe revenue streams are are short to come.

In my oppinion, based on the successfulness of Dr Hensley and the history of Zicam(r), I see a bright and continuing future for Emesyl(r), Dr Hensley, and future products of Itonis Inc.

I believe the current share price of ITNS puts this company well within reach of all potential investors, making this an exceptional investment opportunity.

Tom West, Ogden, UT